Biology and Therapeutic Development for NF1 Associated Cutaneous Neurofibromas

The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is a philanthropic research entity based at Johns Hopkins University School of Medicine dedicated to the discovery of therapeutics for the peripheral nerve tumors that afflict people with Neurofibromatosis Type 1 (NF1).

 

 

Areas of special interest include:
1. Investigate the processes underlying the stages of cNF initiation, progression, maintenance and senescence.
2. Identify and validate therapeutic candidates across the various stages and expressions of cNF
3. Identify or validate non invasive approaches in humans and preclinical systems for detection and assessment of growth or response of cNF
4. Define or validate key variables and endpoints for cNF clinical trials.

5. Develop the infrastructure for patient driven engagement programs to enable registries and rapid enrollment into clinical trials for cNF

 

 

 

 

Funding: $300,000 to $1,000,000 total 

Duration: 1-3 years

 

 

It is expected that 15 awards will be granted. 

 

 

 

 

Research Authority due date: 28.7.22